NEW YORK, Sept. 10, 2015 /PRNewswire/ -- Meningococcal disease, especially meningococcal meningitis, is one of the most catastrophic infections among individuals or communities. Several meningococcal serogroups have been identified till date, of which serogroups A, B, C, Y, and W-135 are the most prominent ones causing the infection. Meningococcal disease is a life threatening condition and potentially fatal illness caused due to the bacterium Neisseria meningitidis. It causes serious infection of the thin layers of connective tissue surrounding the brain and spinal cord called the meninges. Immunization by vaccines has been of great help to public health. It has saved millions of children and provided them with a chance of better and healthier life. Many diseases have been eradicated, while some have been better controlled. Thus vaccines are considered as the most powerful form of all preventive measures. Meningococcal disease is one such disease which has a high mortality rate if left undiagnosed and untreated. Meningococcal vaccines are used to prevent diseases such as meningitis, meningococcemia and septicemia, caused due to N. meningitidis.
According to a report by CDC, incidences of bacterial meningitis have dropped by almost a third over the past decade due to stringent regulations, awareness and initiatives taken by the government as well as the citizens. The global meningococcal vaccines market is studied on the basis of vaccine types such as polysaccharide, conjugate, and combination vaccines that are further segmented into different brands. The report also highlights and analyzes various brands of Men B vaccines recently approved, such as Bexsero and Trumenba, as well as the vaccine currently in pipeline - NmVac-4DT. A detailed market analysis and forecast for these segments has been provided in this study, in terms of revenue (USD million) for the period 2012 to 2022. The report also provides the compounded annual growth rate (CAGR %) for each meningococcal vaccine segment and brand for the forecast period 2014 to 2022, while market size estimations have been made considering 2012 and 2013 as the base years.
In terms of geographical distribution, the global meningococcal vaccines market has been classified into four major geographical areas, namely North America, Europe, Asia-Pacific and Rest of the World (RoW). The regions are further broken down by major countries. The current and future market sizes (in terms of USD million) of the mentioned regional markets and their major countries have been provided in the report for the period 2012 to 2022 with their growth rate (%) for the period 2014 to 2022. The study further offers recommendations and highlights of the market, which would be useful for the current and future market players to sustain and flourish in the global meningococcal vaccines market.
The global meningococcal vaccines market overview section of the report demonstrates the market dynamics and market trends such as drivers, restraints and opportunities that influence the current and future status of meningococcal vaccines industry. Impact factors such as market attractiveness analysis and Porter's five forces analysis have also been explained in the market overview section of the global meningococcal vaccines report, in order to give a thorough analysis of the overall competitive scenario in the global meningococcal vaccines market. The global meningococcal vaccines market report also covers qualitative information on certain areas in market overview section which include clinical features, epidemiology, diagnosis and treatment for meningococcal disease, types of meningococcal vaccines, and regulatory scenario.
The report concludes with the company profiles section which includes key information about the major players in this market. Key players profiled in this report include Sanofi S.A., Novartis International AG, GlaxoSmithKline plc, Pfizer, Inc., Serum Institute of India, Ltd., JN-International Medical Corporation, Nuron Biotech, Baxter International and Biomed Pvt. Ltd.
The global meningococcal vaccines market is segmented as follow:
Meningococcal Vaccines Market, by Type
Polysaccharide Vaccines, by Brand
Conjugate Vaccines, by Brand
Combination Vaccines, by Brand
Men B Vaccines, by Brand
Meningococcal Vaccines Market, by Geography
Rest of Europe
Rest of Asia Pacific
Rest of the World
Rest of RoW
Read the full report: http://www.reportlinker.com/p02912629-summary/view-report.html
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: firstname.lastname@example.org
US:(339) 368 6001
Intl:+1 339 368 6001